Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1NET 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 334Carcinoma, Renal Cell 112Urinary Bladder Neoplasms 95Breast Neoplasms 55Carcinoma, Transitional Cell 52Colorectal Neoplasms 43Carcinoma, Non-Small-Cell Lung 42Melanoma 41Ovarian Neoplasms 39Kidney Neoplasms 39Neoplasms 38Neoplasm Metastasis 31Lung Neoplasms 28Sarcoma 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Pancreatic Neoplasms 24Endometrial Neoplasms 23Stomach Neoplasms 22Wilms Tumor 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Hepatocellular 19Esophageal Neoplasms 18Adenocarcinoma 18Triple Negative Breast Neoplasms 17Head and Neck Neoplasms 17Small Cell Lung Carcinoma 15Thyroid Neoplasms 14Metastatic Castration-resistant Prostate Cancer 14Neuroblastoma 13

Interventions

ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Genitourinary × 30 days × Clear all
NCT07574541 2026-06-04

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡